Dr. Helen I. Torley is the CEO of Halozyme Therapeutics, Inc., bringing over 30 years of experience in the biotechnology and pharmaceutical industry. She earned her M.B.Ch.B. from the University of Glasgow. Before becoming CEO in 2014, she held significant...

Dr. Helen I. Torley is the CEO of Halozyme Therapeutics, Inc., bringing over 30 years of experience in the biotechnology and pharmaceutical industry. She earned her M.B.Ch.B. from the University of Glasgow. Before becoming CEO in 2014, she held significant roles at Onyx Pharmaceuticals and Amgen, where she successfully launched several drugs including Kyprolis and Prolia. Under her leadership, Halozyme has seen a strategic shift that contributed to its successes in drug development and commercialization. Dr. Torley also has a strong background in medicine, having trained as a doctor and worked in clinical settings. Her ability to connect scientific advances with business strategies has been key to Halozyme’s growth. Notably, Dr. Torley’s total compensation for 2022 was around $1.4 million, which reflects her performance-based bonus structure and stock vesting achievements. Her trading activities with Halozyme stocks indicate a significant confidence in her work, with insider trading values reaching as high as $54.53 million in early 2021. This suggests not just a commitment to the company but also a vested interest in its future.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Halozyme Therapeutics CEOs

H

Dr. Helen I. Torley, M.B., Ch.B, M.R.C.P.

CEO of Halozyme Therapeutics

Education

M.B.Ch.B from the University of Glasgow

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1962 - 63 years ago

CEO of Halozyme Therapeutics for

11 years 4 months (Jan 2014 - Present)

Previous Experience

Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals

Rivals

Competitors/colleagues of Dr. Helen I. Torley, M.B., Ch.B, M.R.C.P.

Holdings

See how much did Dr. Helen I. Torley, M.B., Ch.B, M.R.C.P. make over time.

Dr. Torley’s holdings in Halozyme reflect a strong belief in the company’s future. Her insider trading activities show significant fluctuations in value over the years, notably peaking at around $54.53 million in February 2021. This peak followed the company’s successful...

Dr. Torley’s holdings in Halozyme reflect a strong belief in the company’s future. Her insider trading activities show significant fluctuations in value over the years, notably peaking at around $54.53 million in February 2021. This peak followed the company’s successful strategic initiatives that she led. In 2022, her holdings were valued at approximately $40.91 million, alongside several instances of selling shares that were well-timed with market conditions. As the company's performance improved, so did the value of her holdings. From 2019 to 2024, there were consistent increases in her holdings' value, indicating her ongoing confidence in Halozyme’s direction and potential. Overall, her investments demonstrate a strong alignment with the company's goals and achievements.

Mar 17, 2025

H

shares

HALO @ $62.95

Total Stock Sold

$41.93M

HALO

$41.93M

911,061 HALO shares

What if they kept their stock?

If Dr. Helen I. Torley, M.B., Ch.B, M.R.C.P. didn't sell their stock, today they would have:
Extra HALO911,061 shares worth $21.80M.
This is -48% and $20.13M less than what they got when they sold the stock.

Charitable Transactions

HALO

52,500 shares

HALO

Recent Charitable Transactions

HALO

10,000 shares

HALO

Nov 29, 2024

Charity

HALO

10,000 shares

HALO

Mar 1, 2023

Charity

HALO

10,000 shares

HALO

Nov 30, 2020

Charity

HALO

10,000 shares

HALO

Aug 14, 2020

Charity

HALO

12,500 shares

HALO

Dec 31, 2019

Charity

Insider Trading

See recent insider trades of Dr. Helen I. Torley, M.B., Ch.B, M.R.C.P..

HALO

10,000 shares

HALO

Nov 29, 2024

Charity

HALO

$1.07M

HALO at $53.52/share

Oct 8, 2024

Sale

HALO

$1.71M

HALO at $56.88/share

Sep 24, 2024

Sale

HALO

$1.77M

HALO at $59.13/share

Sep 10, 2024

Sale

HALO

$1.72M

HALO at $57.26/share

Aug 13, 2024

Sale

HALO

32,781 shares

HALO

Feb 15, 2024

Received

HALO

$1.28M

HALO at $42.69/share

Aug 29, 2023

Sale

HALO

$1.30M

HALO at $43.49/share

Aug 15, 2023

Sale

HALO

$1.29M

HALO at $43.09/share

Jul 25, 2023

Sale

HALO

$1.31M

HALO at $43.82/share

Mar 7, 2023

Sale

Compensation History

See how much did Dr. Helen I. Torley, M.B., Ch.B, M.R.C.P. make over time.

In 2022, Dr. Helen Torley's total compensation as CEO of Halozyme Therapeutics was approximately $1.4 million. This included a base salary of $920,000, a performance-based bonus of around $883,476 that reflected strong company performance against corporate goals, and vested stock that added significant value. Notably, the compensation strategy aligns with Halozyme’s growth metrics, emphasizing revenue growth and adjusted EBITDA targets. Over previous years, her compensation has reflected both her leadership success and the company’s strategic achievements. For instance, her total compensation in 2020 was around $1.4 million, slightly higher than in 2021, but varied significantly, with peak earnings of over $5.7 million in 2018, highlighting the variability tied to performance outcomes. This structured approach underlines her commitment to driving long-term value for shareholders.

Year

2022

Total Compensation

$6.62M

Salary

$920.00K

Board Justification

The compensation philosophy aligns executive compensation with the achievement of key strategic, financial, and operational goals, emphasizing long-term performance and stockholder value.

Bonus

$883.48K

Board Justification

The annual cash incentive earned for 2022 was based on the performance of the Company against pre-established corporate performance goals, achieving approximately 107% of her target annual cash incentive opportunity.

Other

$0.00

Board Justification

Restricted Stock

$4.81M(98.18K RSU)

Board Justification

The number of RSUs that vested in 2022, based on the vesting schedule of 25% annually over four years following the grant date, subject to continued employment.

Performance Metrics

The performance metrics for determining the CEO's compensation included revenue growth and adjusted EBITDA targets.

Other Halozyme Therapeutics CEOs

Here are other CEOs of Halozyme Therapeutics

Gregory I. Frost, Ph.D.

Founder and Ex-CEO of Halozyme Therapeutics

December 2010 - January 2014